Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Respirology Case Reports|December 30, 2016
Pemetrexed for epithelioid haemangioendothelioma of the pleuraShingo Kanemura, Kozo Kuribayashi, Yumiko Moriya, et al.
Internal Medicine (Tokyo, Japan)|August 20, 2003
Allergic bronchial asthma: airway inflammation and hyperresponsivenessMinoru Sugita, Kozo Kuribayashi, Takayuki Nakagomi, et al.
Molecular and Clinical Oncology|March 21, 2014
Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesotheliomaKazuya Fukuoka, Kozo Kuribayashi, Shusai Yamada, et al.
Cancer Diagnosis & Prognosis|November 7, 2022
Malignant Peritoneal Mesothelioma Features Shown by FDG-PET/CTKozo Kuribayashi, Kazuhiro Kitajima, Toshiyuki Minami, et al.
Anticancer Research|September 26, 2025
Combined Compression and Cooling Therapy for Taxane Chemotherapy-induced Peripheral Neuropathy in Lung CancerYasuhiro Nakajima, Kozo Kuribayashi, Akio Tada, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2011
Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry studyKozo Kuribayashi, Simon Voss, Shinichi Nishiuma, et al.
Cancer Control : Journal of the Moffitt Cancer Center|June 25, 2025
Enhancing Duloxetine With Mirogabalin for Treating Taxane-Induced Peripheral Neuropathy in Advanced Lung CancerYasuhiro Nakajima, Kozo Kuribayashi, Akio Tada, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|December 31, 2014
Adenosine deaminase inhibitor EHNA exhibits a potent anticancer effect against malignant pleural mesotheliomaYasuhiro Nakajima, Takeshi Kanno, Toshio Nagaya, et al.
The American Journal of Pathology|October 7, 2004
The 150-kilodalton oxygen-regulated protein ameliorates lipopolysaccharide-induced acute lung injury in miceTakayuki Nakagomi, Osamu Kitada, Kozo Kuribayashi, et al.
Oncology|December 25, 2022
Clinical Efficacy and Safety of Nivolumab in Malignant Non-Pleural Mesothelioma: A Multicenter, Open-Label, Single-Arm, Japanese Phase II Trial (Viola) ProtocolKozo Kuribayashi, Masataka Igeta, Takashi Daimon, et al.
Pageof 9